Appeals mean no end in sight to Japanese Iressa litigation
This article was originally published in Scrip
Executive Summary
Appeals against rulings by two district courts in Japan in cases involving side-effects attributed to Iressa (gefitinib) have set the stage for a prolonged legal battle over the AstraZeneca lung cancer drug.